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TO THE EDITOR
Xerosis is one of the most common
cutaneous manifestations in HIV infec-
tion. Although reportedly affecting up
to 20–30% of patients with HIV (Rowe
et al., 1999; Lee et al., 2007), the
underlying cause of this xerosis has not
yet been elucidated. In a further sub-
group, xerosis is complicated by an
atopic dermatitis (AD)-like rash or
xerotic eczema. Xerosis is reportedly
more common in HIV-infected indivi-
duals with CD4 cell counts p200 ml–1,
and treatment with protease inhibitors,
such as indinavir, provokes xerosis
even in patients with higher CD4
counts (Lee et al., 2007).
Impaired epidermal barrier function
is now closely linked to the pathogen-
esis of AD (Palmer et al., 2006;
Weidinger et al., 2006; Sandilands
et al., 2007), where defective stratum
corneum (SC) barrier function in turn
predisposes to repeated antigen pene-
tration, leading to Th2-dominant in-
flammation (Fallon et al., 2009;
Scharschmidt et al., 2009). Accord-
ingly, overexpression of the Th2 cyto-
kine (IL-4) in transgenic mice causes
spontaneous AD (Lee and Flavell,
2004). But the chronic barrier abnorm-
ality in AD also stimulates production
of epidermal cytokines and growth
factors that stimulate inflammation
(‘‘cytokine cascade’’), eventually re-
cruiting Th2 cells, which in turn pro-
duce cytokines, such as IL-4, that
further compromises barrier function
(‘‘outside-inside-back to outside’’)
hypothesis (Elias and Steinhoff, 2008;
Elias et al., 2008).
Although it is widely believed that
HIV-associated xerosis and xerotic ec-
zema reflect a worsening of pre-existent
AD (Parkin et al., 1987; Cockerell
1991), HIV infection itself provokes a
Th2 immunophenotype (Klein et al.,
1997), and as noted above, Th2 cyto-
kines themselves downregulate barrier
function (Kurahashi et al., 2008), as
well as ceramide synthesis (Hatano
et al., 2005), and expression of several
differentiation-related structural pro-
teins (Howell et al., 2007, 2008).
Hence, we hypothesized that a pri-
mary, infection-triggered Th2-dominant
immune abnormality could drive sub-
sequent epidermal changes in HIV.
Accordingly, we assessed here cuta-
neous permeability barrier status in a
cohort of HIVþ subjects, with no
previous or current history of either
AD or mucosal atopy. These HIVþ ,
non-atopic patients display abnormal
basal barrier function that becomes
much more prominent in a sub-
group of HIVþ patients with xerotic
eczema. Moreover, CD4þ cell
nadirs (o150ml–1) correlated signifi-
cantly with prominent skin dryness,
but in this non-atopic cohort, anti-
retroviral therapy aggravated neither
barrier function, xerosis, nor SC hydra-
tion, suggesting that protease inhibitor
(PI)-related xerosis and xerotic eczema
could occur primarily or only in HIVþ
patients with previous or concurrent
AD/atopy.
We first assessed basal barrier func-
tion over non-lesional skin sites in 21
HIVþ patients (age 47±SD 7.4, two
female patients) and six age, sex, and
pigment-type matched controls (age
45±SD 9.6, one female patient). The
mean duration of HIV infection in these
subjects was 12.1±SD 6.4 years. A
random group of seven HIVþ patients
was genotyped for the three most
common filaggrin mutations (that is,
R501X, 2282del4, and R2447X), and
none carried mutations, despite the fact
that several of the patients showed
abnormal barrier function and clinical
xerosis (Supplementary Table 1). Most
of our patients were on treatment with
anti-retroviral drugs (n¼ 17, 81%), in-
cluding a protease inhibitor (n¼13,
62%). Nine patients displayed clini-
cally normal skin, whereas nine others
had xerosis, and a further three patients
displayed xerosis plus generalized xero-
tic eczema. HIVþ patients with no
signs of eczema displayed abnormal
basal barrier function (Figure 1a), in-
cluding subjects without xerosis (E3-
fold increase in transepidermal water
loss (TEWL) rates (6.4±0.7 vs 2.2±0.3;
Po0.001). Finally, even patients who
were off antiretroviral treatment dis-
played elevated TEWL rates, showing
that the barrier abnormality in HIVþ
patients cannot be ascribed to antire-
troviral therapy.
The barrier abnormality became
much more prominent in a subgroup of
three patients with xerotic eczema
(10.5±1.1 vs 2.2±0.3, Po0.001), and
these patients displayed significantly
reduced SC hydration (35.3±3.2 vs
53.2±2.0, P¼0.002) and a higher sur-
face pH (6.0±0.6 vs 5.2±0.1, Po0.05),
compared with HIV patients without
eczema (Figure 2). Finally, SC integrity/
cohesion, surface pH, SC hydration and
barrier recovery kinetics did not signifi-
cantly differ in the HIVþ versus control
groups as a whole (Figure 2).
We next assessed epidermal func-
tion in relation to patients’ historically
lowest CD4 counts (CD4 nadir) in these
continuously monitored patients. Bar-
rier function was abnormal in HIVþ
patients, whether CD4 nadirs were less
than or greater than 150ml–1 (data not
shown). Similarly, SC integrity/cohesion
and barrier recovery rates were com-
parable in patients with low CD4 nadirs
versus nadirs 4150ml–1 (not shown).
Although HIV patients with CD4þ
nadir o150 ml–1 displayed worse sub-
ject- and physician-rated visual dryness
Abbreviations: AD, atopic dermatitis; KLK, kallikrein; PI, protease inhibitor; RA, retinoic acid; SC, stratum
corneum; TEWL, transepidermal water loss
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(Figure 3, Po0.05), SC hydration mea-
surements did not correlate with either
subject- or physician-rated skin dry-
ness. But patients with the lowest CD4
nadirs displayed a significantly higher
surface pH (5.56±1.8 vs 5.0±0.16,
Po0.05). Finally, skin dryness did not
correlate with current CD4 cell counts
or viral load.
Although HIV-related xerosis report-
edly occurs more commonly in patients
receiving antiretroviral treatment with
protease inhibitors (Garcia-Silva et al.,
2000; Lee et al., 2007), in this non-AD
cohort, skin dryness, as rated either by
the subjects or by physicians, did not
worsen in patients on anti-retroviral
therapy, including protease inhibitors.
Furthermore, their basal TEWL, SC
hydration, SC integrity, surface pH
and barrier recovery kinetics did not
differ significantly from untreated HIV
patients. Although our results could
reflect the low numbers of patients in
this study, these results suggest that
antiretroviral therapy did not adversely
affect the cutaneous function in non-
atopic HIV.
COMMENTS
Xerosis and xerotic eczema are fre-
quent, troublesome side effects of HIV
infection. The Study of Fat Redistribu-
tion and Metabolic Change in HIV
Infection (FRAM Study) reported a high
prevalence of dry skin in a large cohort
of HIVþ patients versus controls (Lee
et al., 2007). Moreover, xerosis was
associated with lower CD4þ counts,
current protease inhibitor (PI) use,
and recent opportunistic infections.
Although xerosis has also been linked
to PI use in several other studies (for
example, Garcia-Silva et al., 2000), the
mechanism(s) that lead(s) to HIV-asso-
ciated dry skin and xerotic eczema
is(are) not known. One prevalent hy-
pothesis holds that PI displace retinoic
acid (RA) from its cytosolic receptor,
making higher levels of free RA avail-
able to provoke xerosis (Lee et al.,
2007). Alternatively, depletion of cuta-
neous peptidergic innervation, affecting
either the nutrient supply of the upper
dermis, and/or secretory activity of
sweat glands, has also been proposed
to account for HIV-associated xerosis
(Rowe et al., 1999). Interestingly,
though increased transcutaneous water
loss inevitably leads to xeric stress
(lower SC hydration), epidermal perme-
ability barrier function has not yet been
examined in HIV infection.
A primary barrier abnormality un-
derlies AD in HIV-negative subjects,
and it is widely believed that xerosis
and xerotic eczema occur primarily in
subjects with previous or concurrent
AD (Parkin et al., 1987; Cockerell
1991). To examine this issue, we
assessed the epidermal function in a
small cohort of non-atopic HIVþ
patients. We show here that barrier
dysfunction and xerosis occur in pa-
tients without an atopic background,
and barrier function is abnormal even
in HIVþ patients without xerosis. As
barrier function worsened in a small
subgroup of patients with xerotic ecze-
ma, barrier dysfunction in HIV-related
xerosis and xerotic eczema could re-
present stages of disease progression
along a disease continuum. Thus, all of
the functional abnormalities that char-
acterize clinical xerosis, including ab-
normal barrier function and xerotic
eczema occur frequently in patients
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Figure 1. Abnormal barrier function in HIV patients, independent of anti-retroviral therapy. (a) HIVþ
patients displayed abnormal basal barrier function that became more prominent in a subgroup with
xerotic eczema. Basal TEWL was measured in the interscapular skin using Tewameter at ambient clinic
temperatures (22–251C) and at a relative humidity of 40–60% after 15minutes acclimatization. HIV
patients displayed higher basal TEWL rates, which increased further in patients with xerotic eczema.
(b) Abnormal barrier function in HIVþ patients is not attributable to antiretroviral therapy. HIVþ
patients displayed abnormal basal barrier function, regardless of their antiretroviral treatment status.
Abbreviation: TEWL, transepidermal water loss.
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Figure 2. Patients with HIV-related xerotic eczema displayed lower SC hydration and higher pH,
but comparable SC integrity and barrier recovery kinetics. Stratum corneum (SC) hydration of the
interscapular skin was measured using corneometer. Surface pH was measured with a flat-glass electrode
attached to a precision pH meter. SC integrity was assessed as the percentage increase in the TEWL
after sequential tape stripping with 15 D-squame tapes. TEWL was read at 3 hours after tape stripping and
barrier recovery was calculated as described in text. The dotted lines indicate mean values for control
subjects. Abbreviation: TEWL, transepidermal water loss.
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with non-atopic HIV. Furthermore, we
found an elevated SC pH in patients
with xerotic eczema, which could
contribute to the pathogenesis of barrier
dysfunction by multiple downstream
mechanisms (Elias et al., 2008; Cork
et al., 2009). For example, increased
pH is known to activate serine pro-
teases (kallikreins) (Hachem et al.,
2002, 2003, 2009), and kallikrein5
itself upregulates an epidermis-initiated
cytokine cascade that induces Th2
inflammation (Briot et al., 2009). As
visual dryness did not correlate with SC
hydration measurements, HIV-related
xerosis is not a true ichthyosis,
but rather likely a hyperproliferative
response in response to impaired bar-
rier function (Proksch et al., 1991).
Moreover, SC integrity (cohesion)
was normal in these subjects, another
distinguishing feature from ichthyosis.
HIV disease, like AD, is itself asso-
ciated with a Th2 cytokine profile
(Klein et al., 1997), which correlates
with reduced CD4 counts (Tsunemi
et al., 2005), and xerosis was worse in
our patients with low CD4 nadirs. As
our patients were non-atopic, the puta-
tive increase in Th2 cytokines could
provoke barrier dysfunction by: (1)
reduced epidermal differentiation
(Howell et al., 2008), (2) decreased
epidermal ceramide production (Hatano
et al., 2005), and/or (3) decreased
epidermal e-cadherin production
(Kobayashi et al., 2004). In contrast to
AD, this view of disease pathogenesis
suggests an opposite, ‘‘inside-to-outside’’
mechanism as the initial trigger of
epidermal dysfunction in HIV. A possible
explanation for the progressive worsen-
ing of the AD-like phenotype in some
HIV patients could be the fact that the
defective barrier allows sustained anti-
gen penetration, which further accentu-
ated Th2 cytokine production, (Elias
et al., 1999; Taieb, 1999). This sequence
would then result in a hypothetical initial
‘‘inside-to-outside,’’ followed by a
‘‘back-to-inside’’ vicious circle in HIV
(Supplementary Figure 1). Accordingly,
in non-atopic HIV subjects, antiretroviral
drugs (including PI) that correct the
primary immune abnormality could be
expected to improve, rather than worsen
xerosis. Yet, if the abnormality in barrier
function persists, allowing sustained anti-
gen penetration, cutaneous inflammation
would persist, even after T-cell balance
has been partially restored by anti-retro-
viral therapy. This concept could explain
why the incidence of HIV-related xerosis
has not changed significantly, despite
advances in HIV treatment that have
reduced other dermatological complica-
tions (Hengge et al., 2000).
Written, informed consent was obtained
from all participants before enrollment, and
all clinical investigations were conducted
according to the Declaration of Helsinki
principles. The research protocol was
approved by the human studies commit-
tees at the University of California San
Francisco and Veteran Affairs Medical
Center, San Francisco.
Complete methods are available on-
line; see figure legends for some details.
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Genetic Diversity in Melanoma Metastases from a
Patient with Xeroderma Pigmentosum
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TO THE EDITOR
Melanoma is among the most severe and
lethal forms of human skin cancer
(Mackie, 2006; Miller and Mihm Jr,
2006; Fecher et al., 2007; Gray-Schopfer
et al., 2007). For 2008, more than
110,000 new cases of melanoma (about
50,000 melanoma in situ (MIS) and
60,000 invasive melanomas) were esti-
mated with more than 8,000 deaths
(American Academy of Dermatology,
2008; Ries et al., 2008). To examine
genetic diversity, we studied metastatic
melanoma lesions from a patient with
xeroderma pigmentosum (XP). XP is a
rare genetic disease with defective DNA
repair and a more than 1000-fold in-
crease in melanoma frequency (Kraemer
et al., 1987, 1994; Ruenger et al., 2008).
The XP patient, (XP4BE), had no
blistering reaction to sunlight despite
living on a farm with unrestricted
exposure to sunlight. By 8 years of age
he had extensive freckling on his face
(Figure 1a). At the age of 9 years a large
warty tumor was excised from his nose.
He subsequently developed more than
100 cancers in sun-exposed skin, pri-
marily basal cell carcinomas and squa-
mous cell carcinomas, which were
treated with electrodessication and
curettage or surgical excision followed
by skin grafting (Figure 1b). At the age
of 23 years a primary malignant mela-
noma of the right post-auricular area
had been widely excised, and evidence
of spread was found in two of the
35 posterior cervical nodes.
XP4BE was admitted to the NIH
Clinical Center in 1969 at the age of 25
years (Robbins et al., 1974) and studied
in accordance with the NIH human
research guidelines then in eff-
ect. He was the first XP ‘‘variant’’ patient
recognized, a form of XP with normal
nucleotide excision repair (Robbins et al.,
1974). His cells were subsequently found
to have a defect in the error-prone
polymerase, polymerase eta (Johnson
et al., 1999; Masutani et al., 1999). At
admission, his neurological examination
was normal. In 1971, a melanoma
nodule was present on his scalp (Figure
1c). He had no beneficial response to
two courses of bis-choroethyl-nitrosourea
(BCNU), steroids, or radiation to the
brain and lumbar areas for treatment of
the metastatic melanoma. He died at the
age of 27 years in 1971. Autopsy
performed at NIH revealed thromboem-
boli with pulmonary infarctions, asper-
gillus pneumonia and cerebral abscess,
and metastatic melanoma involving his
brain, spinal cord, stomach, small bowel,
liver, gall bladder, adrenal glands, kid-
neys, lymph nodes, left testis, right lung,
pancreas, thyroid gland, and soft tissue of
the right thigh. The paraffin blocks from
this autopsy were recently retrieved,
sectioned, and stained. We do not have
tissue from the primary lesion, which was
removed before coming to NIH.
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